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Inverse planned intensity modulated radiotherapy sIMRTd fields can be highly modulated due to the
large number of degrees of freedom involved in the inverse planning process. Additional modula-
tion typically results in a more optimal plan, although the clinical rewards may be small or offset by
additional delivery complexity and/or increased dose from transmission and leakage. Increasing
modulation decreases delivery efficiency, and may lead to plans that are more sensitive to geometri-
cal uncertainties. The purpose of this work is to assess the use of maximum intensity limits in
inverse IMRT planning as a simple way to increase delivery efficiency without significantly affect-
ing plan quality. Nine clinical cases sthree each for brain, prostate, and head/neckd were used to
evaluate advantages and disadvantages of limiting maximum intensity to increase delivery effi-
ciency. IMRT plans were generated using in-house protocol-based constraints and objectives for the
brain and head/neck, and RTOG 9406 dose volume objectives in the prostate. Each case was
optimized at a series of maximum intensity ratios sthe product of the maximum intensity and the
number of beams divided by the prescribed dose to the target volumed, and evaluated in terms of
clinical metrics, dose-volume histograms, monitor units sMUd required per fraction sSMLC and
DMLC deliveryd, and intensity map variation sa measure of the beam modulationd. In each site
tested, it was possible to reduce total monitor units by constraining the maximum allowed intensity
without compromising the clinical acceptability of the plan. Monitor unit reductions up to 38%
were observed for SMLC delivery, while reductions up to 29% were achieved for DMLC delivery.
In general, complicated geometries saw a smaller reduction in monitor units for both delivery types,
although DMLC delivery required significantly more monitor units in all cases. Constraining the
maximum intensity in an inverse IMRT plan is a simple way to improve delivery efficiency without
compromising plan objectives. © 2005 American Association of Physicists in Medicine.
fDOI: 10.1118/1.1895545gI. INTRODUCTION
The introduction of inverse planned intensity modulated ra-
diotherapy sIMRTd into clinics has allowed improvement in
many areas of therapy, including dose escalation, reduction
of normal tissue toxicity, simultaneous boost treatments, and
a high degree of dose conformity and coverage that may not
have been possible with conventional three-dimensional
s3Dd conformal therapy.1–9 Such improvements are possible
not just because of the ability of inverse planning optimiza-
tion systems to create steep dose gradients between target
and normal tissue interfaces, but also because of their ability
to place dose in a nonintuitive fashion scompared to a for-
ward planned techniqued. Since inverse planning is a discrete
optimization problem with many variables, IMRT beams
have the potential to be discontinuous, with very sharp gra-
dients over small distances. On one hand, these features are
considered desirable because they help achieve the objec-
tives given to the treatment planning system. On the other
hand, these features can lead to undesirable effects, including
large increases in monitor units sMUd, sensitivity to geomet-
ric uncertainties, inaccurate leaf sequencing, and prolonged
delivery times.10–13 Another concern is the additional dose
delivered to the patient from transmission and leakage as
14,15MU are increased. As intensity patterns become more
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, May 2005 0094-2405/2005/325/1complex, the differences between the computed, sequenced,
and delivered intensity patterns may increase. This may be-
come an important issue as those involved in the planning
process gain more experience and use increasingly strict
specifications in the objective function.
The difficulties associated with complex intensity patterns
have motivated attempts to increase the efficiency of IMRT
delivery as well as to reduce unnecessary modulation in de-
livered IMRT beams.10 To prevent cases of inaccurate se-
quencing and make the optimization process more efficient
with respect to delivery, IMRT delivery constraints have
been incorporated directly into the optimization
process12,16–18 and improvements in efficiency have been ob-
tained with advances in leaf sequencing algorithms.19–23
Much effort has also been devoted to incorporation of
smoothing algorithms during or after optimization, to pro-
duce more continuous intensity patterns that reduce undeliv-
erability as well as excessive MU.10,11,13,24–26
Another possible strategy is to acknowledge that some of
the high intensity peaks may result from limitations in the
inverse planning optimization strategy and may not be essen-
tial for high quality plans. If so, then constraining the maxi-
mum allowable intensity for an IMRT plan may inhibit the
optimization engine from pursuing an undesirable path that
may be an artifact of the point-based inverse planning ap-
1234234/12/$22.50 © 2005 Am. Assoc. Phys. Med.
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optimization process can result in beamlet patterns that lack
potentially unnecessary modulation and sharp spikes, while
still allowing the optimization algorithm to make the proper
tradeoffs between target and normal tissue doses. This ap-
proach, which is the focus of the current work, would ideally
produce a plan that will be sequenced more accurately, de-
livered with fewer MUs, and less sensitive to positioning
errors than an IMRT plan derived without maximum inten-
sity limits, while still achieving the defined clinical objec-
tives. The purpose of this paper is to evaluate both the de-
livery improvements and changes in plan quality that result
from applying intensity limits during inverse plan optimiza-
tion to a series of prostate, brain, and head/neck plans.
II. METHODS
All inverse planning and analysis for this study was per-
formed with our in-house-developed 3D planning
sUMPLANd27–31 and inverse planning sUMOPTd32,33 systems.
All cases were optimized with 6 MV beamlet IMRT planned
for a 6 MV linear accelerator sVarian Medical Systems,
21EXd with 120 leaf multileaf collimator sMLCd s0.5 and 1.0
cm leaf widthsd. Dose calculations for the inverse planning
system were performed with a convolution/superposition al-
gorithm derived from the work of Mackie.34 All cases were
optimized using a quasi-Newton-based search strategy, incor-
porating dose, dose–volume, and biological-based costlets
designed to meet each of the specified planning protocols.
Simulated annealing was also used, to ensure that the opti-
mized plans did not represent local minima of the cost func-
tion. Leaf sequencing for SMLC delivery was performed
with an in-house-developed leaf sequencer based on the
method reported by Bortfeld et al.,35 using the parameters
routinely selected for our clinical IMRT plans. Delivery se-
quences can be up to 250 segments per beam, with the goal
of achieving a correspondence between planned and deliv-
ered intensities of 1.0%. Similarly, plans were sequenced for
dynamic delivery using an in-house sequencer with partial
leaf synchronization and a 150 segment limit.22,36–40
To assess the value of limiting maximum intensity in an
effort to improve delivery efficiency in IMRT, we tested the
procedure in three different clinical sites: brain, prostate, and
head/neck. The sites and specific plans were chosen to rep-
resent a range of complexity and clinical tradeoffs between
target coverage and normal tissue sparing. Three cases each
were studied for each site snine cases totald. After applying
clinical-based cost functions, each plan was optimized using
a series of assigned values of the maximum beamlet inten-
sity. Each plan was also optimized without using a maximum
intensity limit to represent the unconstrained solution. In the
text, these plans are referred to as the unconstrained intensity
plans and the maximum intensity ratio fsee Eq. s1dg is calcu-
lated based upon the highest occurring beamlet value in the
plan. Because the required maximum intensity per beamlet is
technique and dose prescription dependent, the maximum in-
tensity ratio was chosen as a metric to permit direct compari-
Medical Physics, Vol. 32, No. 5, May 2005son of plans with different prescriptions or number of beams.
The “maximum intensity ratio” or MIR, is defined as
MIR =
ImaxNb
Dt
, s1d
where Imax is the maximum intensity allowed for each beam-
let, Nb is the number of beams in the plan, and Dt is the
prescribed dose to the target volume. In this study, Imax is set
for a plan so that no beamlet defined in the plan can exceed
the maximum intensity. Note that the utility of the maximum
intensity ratio for comparing plans from treatment sites with
large geometrical differences will be limited.
Another metric, the intensity map variation, was defined
for each field and used to measure the modulation across a
beam. The plan intensity map variation sPIMVd is calculated
by summing the variation for each field and is defined for
each plan as
PIMV = o
n=1
Nb Fo
j=1
J−1
o
k=1
K−1
suIjk − Ij,k+1u
+ uIjk − Ij+1,ku + uIjk − Ij+1,k+1udG , s2d
where Nb is again the number of beams in the plan, J is the
maximum number of beamlets in the direction parallel to the
motion of the MLC, K is the maximum number of beamlets
in the direction perpendicular to the motion of the MLC, and
Ijk is the intensity of the beamlet at the (j ,k) grid position.
We have chosen the PIMV to be a measurement of the field
modulation that is not biased by the sequencing algorithm
chosen. For this study, each beam was defined as a regular
grid, however, if a beam was defined as segments or an ir-
regular grid, it would be necessary to apply a grid based on
the smallest beamlet dimension and then use Eq. s2d to cal-
culate the PIMV.
For a measure of the similarity between two intensity
maps for plans at different maximum intensity ratios, we
computed the correlation coefficient for each intensity grid
with respect to the unconstrained optimized intensity grid.
Thus, for one beam, given an optimal intensity map at a
maximum intensity ratio of A, and another optimal intensity
map at a maximum intensity ratio of B, we can define the
correlation coefficient as
CIAIB =
o joksIA,jk − IAdsIB,jk − IBd
˛so joksIA,jk − IAd2dso joksIB,jk − IBd2d
, s3d
where j and k are the dimensions of the intensity map fas
discussed in Eq. s2dg, IXjk is the intensity of grid element
(j ,k) when the maximum intensity ratio is X, and IX is the
mean intensity of grid IX. The correlation coefficient may
vary from −1.0 to 1.0. A value of 1.0 means that the two
patterns are perfectly linearly and positively correlated, while
a value of −1.0 means that the two patterns are perfectly
linearly and oppositely correlated. A high absolute number
means there is a high level of correlation, while a small
absolute number represents a weak correlation.
1236 Coselmon et al.: Intensity limits for IMRT inverse planning 1236The effect of limiting the maximum intensity for each
plan was evaluated by determining the total plan monitor
units required for one fraction for both SMLC and DMLC
delivery, the plan intensity map variation, and the clinical
acceptability of the optimized plan. Also, the correlation co-
efficient was determined between intensity maps with vary-
ing maximum intensity ratios. Clinical acceptability was
judged by individual plan dose volume histograms and spe-
cific dose metrics. For each case, the lowest maximum inten-
sity ratio at which clinical acceptability was reached is re-
ported, although we would expect this number to change
slightly for each individual patient geometry. For the pur-
poses of this study, we defined a clinically acceptable plan as
one that met the planning constraints. The level to which a
plan satisfied the planning objectives with respect to the un-
constrained intensity plan was also evaluated.
A. Brain
For the brain test cases, four or five noncoplanar beams,
originally placed by a dosimetrist, were used. The beam
angle information for each of the cases is shown in Table I.
The inverse plan objective function sshown in Table IId was
designed using an in-house IRB approved protocol. Accord-
ing to our protocol, the inner target volume, PTV1, should
receive 66 Gy, with a minimum dose being 95% of the pre-
scription dose with no more than 1% of PTV1 receiving
greater than 105% of the prescription dose and no part of the
volume receiving greater than 110% of the prescription dose.
The outer target volume, PTV2, should receive 60 Gy, with a
minimum dose being 95% of the prescription dose. In addi-
tion, the volume of PTV2 that receives greater than 105% of
the PTV1 prescription dose should be minimized, while still
placing the priority on achieving the prescription dose in
PTV1. For normal tissues, attempts are to be made to limit
TABLE I. Beam angle information for each case.
Casessd Gantrys°d
Brain 1 f270 310 300 240 45g
Brain 2 f270 270 270 90g
Brain 3 f215 285 120 70g
Prostate 1, 2, 3 f0 40 80 120 160 200 240 28
Head/neck 1, 2, 3 f0 51.4 102.9 205.7 257.1 30
TABLE II. Brain protocol objectives.
Structure Objectives
PTV1 66 Gy sminimum 95%, maximum 105%, and 1%
of volume may receive up to 110%d
PTV2 60 Gy sminimum 95%, maximum 105% of PTV1
with PTV1 coverage priorityd
Right optic nerve ł60 Gy
Left optic nerve ł60 Gy
Chiasm ł60 Gy
Brainstem ł65 GyMedical Physics, Vol. 32, No. 5, May 2005the dose to the optic nerves and chiasm to less than 60 Gy,
and the dose to the brainstem to less than 65 Gy.
B. Prostate
For the prostate test cases, we used nine beams at 6 MV
based on work by Pirzkall et al.41 They found that nine
beams were necessary at 6 MV to avoid increased doses to
normal tissue distant from the PTV. Similar to the Pirzkall
work, we applied dose volume objectives according to
RTOG 9406.42 However, instead of defining only the prostate
as the PTV, we used the prostate target volumes employed
routinely in our clinic, which include the prostate with a 5
mm expansion to receive full dose s75.6 Gy for this studyd
and an additional 5 mm margin that receives 54 Gy. The
margin is used because prostate patients in our clinic are
imaged and aligned daily with implanted fiducial markers.43
The beam angle information and target and normal tissue
objectives are given in Tables I and III, respectively. In ad-
dition to those objectives listed, unnecessary dose to unin-
volved normal tissues is to be minimized, and maximum
dose shall not exceed that of the target volumes.
C. Head/neck
For the head/neck geometry, the objective function was
designed using our in-house head/neck IMRT protocol,
which has multiple target prescriptions ssee Table IVd. The
optimization constraints on the targets require that mean tar-
get doses shall be 100% ±3% of the prescribed dose, the
minimum target doses shall be greater than or equal to 93%
of the prescribed dose, and the maximum hot spot in the
target shall be less than or equal to 115% of the prescribed
dose sdelivered to a volume of at least 0.5 ccd. The maximum
dose outside the targets should be less than 105% of the
Collimators°d Tables°d
f0 0 0 0 0g f0 315 270 270 55g
f280 270 270 90g f0 335 290 65g
f0 0 0 0g f0 0 70 70g
0g f0 0 0 0 0 0 0 0 0g f0 0 0 0 0 0 0 0 0g
f0 0 0 0 0 0 0g f0 0 0 0 0 0 0g
TABLE III. Prostate IMRT planning objectives.
Structure Objectives
Prostate+5 mm 75.6 Gy sminimum 95%, maximum 110%d
Prostate+1 cm 54 Gy sminimum 95%, maximum 110% of prostate
+5 mmd
Rectum ł10% volume receives .56 Gy
Bladder ł20% volume receives .60 Gy
Right femur ł10% volume receives .40 Gy smaximum 45 Gyd
Left femur ł10% volume receives .40 Gy smaximum 45 Gyd
Penile bulb ł40% volume receives .50 Gy
Seminal vesicles ł20% volume receives .40 Gy0 32
8.6g
1237 Coselmon et al.: Intensity limits for IMRT inverse planning 1237prescribed dose to PTV1. Normal tissue constraints are given
in Table IV for the spinal cord, brainstem, mandible, and
uninvolved oral cavity. Other objectives include achieving a
mean dose in at least one parotid gland of less than 26 Gy,
and minimizing dose to the uninvolved submandibular
glands and all other uninvolved normal tissue. In cases
where normal structures such as the mandible and oral cavity
overlap target volumes, the strict maximum dose constraints
on those structures may be relaxed to achieve target dose.
III. RESULTS
A. Brain
By employing maximum intensity limits in the brain, it
was possible to achieve clinical acceptability with a substan-
tial decrease in plan intensity map variation and monitor
units when compared to the unconstrained intensity plans.
Table V summarizes the reductions that were possible in
each of the cases tested. Both brain 1 and brain 3 had similar
geometries, while the targets in brain 2 had large areas of
overlap with parts of the brainstem and optic chiasm. Dose
volume histograms for PTV1, PTV2, the right and left optic
nerves, chiasm, and brainstem for brain 1 are displayed for
maximum ratios of 1.15, 1.75, and 3.62 sunconstrained in-
TABLE IV. Head/neck IMRT protocol planning objec
Structure
PTV1
PTV2
Nodal boost PTV
High risk nodal PTV
Low risk nodal PTV
Spinal cord
Spinal cord+5 mm
Brainstem
Right parotid
Left parotid
Mandible
Submandibulars
Oral cavity
TABLE V. Brain, prostate, and head/neck case reductions as compared to the
Case MIR sunconstrainedd MIR sfirst accepted pland
Brain 1 3.62 1.15
Brain 2 2.41 1.15
Brain 3 2.64 1.15
Prostate 1 5.07 1.45
Prostate 2 3.87 1.60
Prostate 3 4.10 1.60
HN 1 3.71 1.45
HN 2 3.00 1.15
HN 3 1.90 1.15Medical Physics, Vol. 32, No. 5, May 2005tensity pland in Fig. 1sad. The corresponding dose distribu-
tions for an axial cut are shown in Fig. 3sbd for both the first
acceptable plan and the unconstrained intensity plan. In all
cases above a maximum intensity ratio of 1.15, coverage of
PTV1 and PTV2 was identical, and all normal tissue con-
straints were met. The unconstrained intensity plan did allow
for slight improvements in normal tissue mean and maxi-
mum doses, which can be seen in Fig. 1sbd. Here we see a
spreading out of the low dose regions into the normal brain
for MIR=1.15. Shown in the top plot of Fig. 2, the maxi-
mum dose metrics for the right optic nerve, chiasm, and
brainstem stay constant due to the maximum dose objectives
in those structures, however, we do see slight decreases in
the maximum dose to the left optic nerve. The mean doses
for all normal structures are reduced slightly as the maxi-
mum intensity is increased, however, these values tend to
converge as the plan reaches higher values of the MIR. The
largest improvements were seen in the mean doses of the
optic chiasm and brainstem, which had dose reductions of
5.0 and 7.3 Gy, respectively, when not applying intensity
limits. Monitor units sMUd were significantly higher in the
unconstrained intensity plan s758 MUd compared to that of
acceptable plans with constrained intensities sstarting at 473
MUd, and the possible reduction in the plan intensity map
Objectives
Gy smean ±3%, minimum 93%, maximum 115%d
Gy smean ±3%, minimum 93%, maximum 115%d
Gy smean ±3%, minimum 93%, maximum 115%d
Gy smean ±3%, minimum 93%, maximum 115%d
6 Gy smean ±3%, minimum 93%, maximum 115%d
5 Gy
0 Gy
4 Gy
an dose ł26 Gy
an dose ł26 Gy
0 Gy
imize dose
s than or equal to 70 Gy
onstrained intensity plans s%d.
MU % reductions
uncon,con s1 s.d.d PIMV % reductions SMLC DMLC
0.80 s0.05d 30.0 37.6 28.8
0.84 s0.09d 18.2 19.0 11.4
0.84 s0.07d 25.5 32.6 24.2
0.69 s0.14d 34.0 30.0 14.0
0.71 s0.08d 27.0 24.8 9.6
0.71 s0.10d 22.5 22.1 0.2
0.85 s0.05d 11.7 23.8 16.8
0.81 s0.03d 31.8 26.7 24.2
0.93 s0.02d 15.3 10.8 9.9tives.
70
60
70
64
57.
ł4
ł5
ł5
Me
Me
ł7
Min
Lesunc
C
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fraction of SMLC delivery as a function of maximum inten-
sity ratio is shown in the bottom plot of Fig. 2. The average
correlation coefficient of the beams compared to the uncon-
strained intensity plan is also shown. As the maximum inten-
sity ratio increases, we see the correlation coefficient of the
beams begin to converge while the MU continue to increase.
Similar trends were seen in brain 2 and brain 3, with the
improvements varying slightly for different normal tissues
depending on the tumor location. An acceptable plan was
achieved with only an 80% average correlation coefficient as
compared to the unconstrained intensity plan beams sfor the
example shownd. Values of the correlation coefficients be-
tween the first acceptable plans and the unconstrained inten-
sity plans are shown in Table V.
B. Prostate
When using maximum intensity constraints in the pros-
tate, it was possible to reduce the number of monitor units
and intensity map variation, while still meeting each of the
planning constraints. The possible reductions in plan inten-
sity map variation, SMLC monitor units, and DMLC monitor
Medical Physics, Vol. 32, No. 5, May 2005units are given in Table V along with the average correlation
coefficients between the unconstrained intensity plans and
the acceptable plans with the lowest MIR values. The mean
and standard deviation of the reduction in MU for SMLC
when compared to DMLC for all inverse plans are also
shown in Table V. For prostate 1, when compared to the first
clinically acceptable plan, reductions in mean dose of 6.5 Gy
in the rectum and 2.6 Gy in the bladder were possible when
removing intensity constraints, but monitor units per fraction
were increased from 847 to 1211 MU. Dose-volume histo-
grams are shown in Fig. 3sad for the prostate
+5 mm, prostate+1 cm, rectum, and bladder at various
maximum intensity ratios. At each maximum intensity ratio
shown, all planning constraints are satisfied, although some
improvement in overall minimization of normal tissue dose
is observed in the unconstrained intensity plan. Figure 3sbd
shows the optimized dose distributions for the first accept-
able plan and the unconstrained plan. We see a different
trend in the dose deposition between the two cases, with the
majority of entrance/exit dose in the anterior/posterior plane
in the intensity limited plan as compared to the uncon-
FIG. 1. Brain case—sad DVHs of PTV1, PTV2, both
optic nerves, chiasm, and brainstem for IMRT plans
with maximum intensity limits sMIR=1.15, 1.75, 3.62d.
Each plan satisfied protocol target and normal tissue
limits. sbd Axial dose distributions for the first accept-
able plan sleftd and the unconstrained intensity plan
srightd. Structure contours shown are PTV1 sblued,
PTV2 swhited, optic nerves sredd, optic chiasm syel-
lowd, and brainstem sgreend.strained intensity plan which appears to rely less on the AP
1239 Coselmon et al.: Intensity limits for IMRT inverse planning 1239FIG. 3. Prostate case—sad DVHs of the prostate+5 mm, prostate+1 cm, the rectum, and the bladder for IMRT plans with maximum intensity limits and an
unconstrained intensity plan sMIR=5.07d. Each plan shown satisfies both target and normal tissue constraints and dose-volume objectives except for MIR
=1.30. sbd Axial dose distributions for the first acceptable plan stopd and the unconstrained intensity plan sbottomd. Structure contours shown are prostateFIG. 2. Brain case—top plot: Normal
tissue mean and maximum doses as a
function of increasing maximum in-
tensity ratio. Bottom plot: Monitor
units per fraction sleftd, and average
correlation coefficient of the fields
srightd, as a function of increasing
maximum intensity ratio. The first
clinically acceptable plan is observed
at MIR=1.15.+5 mm sblued prostate+1 cm svioletd, rectum sbrownd, bladder syellowd, and femurs swhited.
Medical Physics, Vol. 32, No. 5, May 2005
1240 Coselmon et al.: Intensity limits for IMRT inverse planning 1240and PA beams. Figure 4 shows considerable increases in
MU/fraction, with only slight changes in the normal tissue
doses. The top plot in Fig. 4 shows that the maximum and
mean normal tissue metrics stay fairly constant after the first
acceptable plan is reached. The only obvious changes are
increases in the maximum dose delivered to the femurs cor-
responding to very slight reductions in mean dose to the
rectum and bladder. In the bottom plot of Fig. 4, the corre-
lation coefficient converges to one as the MIR reaches its
maximum value for the unconstrained intensity plan. How-
ever, as shown in Table V, we reach an acceptable plan at
only a 69% average correlation with the unconstrained inten-
sity beams and are able to reduce the PIMV by 34%.
C. Head/neck
In the studied head/neck cases, it was possible to achieve
reductions in SMLC and DMLC monitor units per fraction
when using maximum intensity limits during IMRT plan-
Medical Physics, Vol. 32, No. 5, May 2005ning. Table V shows the size of these reductions, the maxi-
mum intensity ratio of the first acceptable plans in each case,
and the average correlation of the beams in these plans ver-
sus the unconstrained intensity plans. It is of interest to point
out that HN 3 had large bilateral boost volumes, possibly
affecting the number of degrees of freedom needed to further
reduce plan complexity. For each case, all planning objec-
tives, including the sparing of the contralateral parotid, were
met. In HN 1, considerable modulation was still necessary
due to the complex geometry, only leading to a 12% reduc-
tion in plan intensity map variation when using maximum
intensity limits. When not limiting the maximum intensity,
slight reductions in the ipsilateral parotid mean doses were
achieved, although it was not possible to spare this parotid
due to its position relative to the target volumes. Normal
tissue dose metrics for HN 1 are shown in Fig. 5 at varying
levels of maximum intensity ratio. In Figs. 6sad and 6sbd,
dose-volume histograms sDVHsd are displayed for all targets
and several normal structures. DVHs in the target volumes
FIG. 4. Prostate case—top plot: Maxi-
mum and mean normal tissue doses as
a function of increasing maximum in-
tensity ratio. Bottom plot: Monitor
units per fraction sleftd, and average
correlation coefficient of the fields
srightd, as a function of increasing
maximum intensity ratio. The first
clinically acceptable plan is observed
at MIR=1.45.are almost identical, while there are visible changes in the
1241 Coselmon et al.: Intensity limits for IMRT inverse planning 1241normal structure DVHs—most noticeably in the brainstem.
In Fig. 6scd, dose distributions are seen for the first accept-
able plan and the unconstrained intensity plan. Both distribu-
tions are similar with only slight changes in the dose depo-
sition patterns. We can see from the top plot of Fig. 5 that the
normal tissue mean and maximum doses are fairly constant
after the first acceptable plan is met. However, there are still
slight changes that can be observed in the mean doses to the
mandible, brainstem, and left parotid and maximum doses to
the right parotid and brainstem as the maximum intensity
limit is increased. The bottom plot in Fig. 5 displays the
increased monitor units necessary to improve the normal tis-
sue DVHs as seen in Fig. 6. Again, we see that the correla-
tion coefficient of the beams relative to the unconstrained
intensity plan converges to one while the monitor units con-
tinue to increase steadily, especially when the maximum in-
tensity is not limited. The first acceptable plan was reached
at an average correlation of 0.85 with the unconstrained in-
Medical Physics, Vol. 32, No. 5, May 2005tensity plan. The difference in the intensity maps as the
maximum intensity ratio increases for a typical beam is
shown in Fig. 7. For each intensity map, the correlation co-
efficient with respect to the unconstrained intensity plan is
shown along with the number of monitor units. Note the
large increase in monitor units for the unconstrained intensity
beam compared to the other plans. We observe that nearly all
beamlets are at the maximum allowed value at MIR=0.85.
As the MIR increases, we continue to see changes in the
beamlet pattern. As we reach MIRs past 1.45, only slight
changes in the high intensity regions of the beam can be
clearly observed. We can see an isolated peak appears toward
the upper left of the field as well as a large region of high
intensity in the upper right of the field. These features, as can
be seen in the DVHs and dose metrics, do not affect the
clinical acceptability of the plan, but do increase the MU
FIG. 5. Head/neck case—top plot:
Mean and maximum normal tissue
doses as a function of increasing maxi-
mum intensity ratio. Mean doses are
solid lines and maximum doses are
dashed lines. Bottom plot: Monitor
units per fraction sleftd, and average
correlation coefficient of the fields
srightd, as a function of increasing
maximum intensity ratio. The first
clinically acceptable plan is observed
at MIR=1.30.significantly.
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Mohan et al. have evaluated many of the difficulties that
arise when dealing with complex intensity patterns, and have
motivated the reduction of unnecessary modulation in IMRT
beams.10 We have proposed maximum intensity limits during
inverse planning as a possible approach to dealing with this
problem. For several clinical sites, the dosimetric advantages
and disadvantages of limiting the maximum beam intensity
were evaluated by optimizing each case at different values of
the maximum intensity ratio, starting at 0.85 up to the maxi-
mum value for the unconstrained intensity plan. In each case,
it was possible to achieve clinical acceptability with substan-
tial decreases in beam modulation and monitor units when
applying maximum intensity constraints. Monitor unit reduc-
tions with SMLC delivery up to 38%, 30%, and 27% were
seen in the brain, prostate, and head/neck, respectively. Cor-
responding decreases for DMLC delivery of up to 29%,
FIG. 6. Head/neck case—sad DVHs of the five target volumes for IMRT p
=3.71d, sbd DVHs of the parotids, cord, brainstem, and mandible, and scd
intensity plan sbottomd. Structure contours shown are PTV1 sblued, PTV2
blued.14%, and 24% were also observed. Also, the plan intensity
Medical Physics, Vol. 32, No. 5, May 2005map variation was reduced by up to 30%, 34%, and 32% in
the brain, prostate, and head/neck. In the head/neck, a some-
what larger degree of beam modulation was necessary and
desirable to reach the planning objectives, and in two of the
three cases in this site, reductions of only 12% and 15% in
plan intensity map variation in the constrained intensity plan
demonstrate that this method is capable of preserving neces-
sary beam modulation while still meeting the specified plan
objectives. As discussed previously, one of the head/neck
cases sHN 3d had a very complex geometry with bilateral
nodal boost volumes, making it difficult to spare normal
structures. However, with the maximum beamlet intensity
limit, it was still possible to reduce SMLC and DMLC MU
by 11% and 10% while meeting critical target coverage and
normal tissue limits.
In similar situations, some smoothing algorithms may be
ineffective at reducing MU without compromising coverage
with maximum intensity limits and an unconstrained intensity plan sMIR
dose distributions for the first acceptable plan stopd and the unconstrained
ed, parotids syellowd, cord+3 mm sgreend, and nodal target volumes slightlans
axial
swhitor sparing due to the sensitive geometry. For example, Sun et
1243 Coselmon et al.: Intensity limits for IMRT inverse planning 1243al. introduced a smoothing procedure based on the structure
index followed by re-optimization of segment weights to im-
prove delivery efficiency. This method was not as effective
in reducing MU in a relatively uncomplicated head/neck ex-
ample having a main GTV and CTV and four normal tissue
objectives.25 For more complicated cases, such as the head/
neck examples used in the current work, the structure index-
based smoothing may be even less effective due to the nu-
merous regions of interest and overlap of structures.
Smoothing algorithms that are applied post-optimization
generally smooth everywhere in the field, therefore they can-
not distinguish between desirable gradients and undesirable
ones, usually resulting in a degradation of the plan according
to the objective function. When smoothing is part of the
objective function, it can be difficult to quantify the direct
tradeoffs that must be made between plan objectives and the
smoothness criteria.10,13 However, promising results have
been shown for plans of average complexity by introducing
smoothness criteria into the cost function at the expense of
decreased delivery efficiency, when compared to methods
that smooth outside of the cost function.13
In the current work with intensity limits, the tradeoff to
achieve increased delivery efficiency is generally an increase
in dose to some of the normal tissues. Examination of the
DVHs in Figs. 1, 3, and 6 shows that the high priority ob-
jectives are met when using the intensity limits, and many of
the differences seen when compared to unconstrained plans
are only in the low dose regions. While it is always preferred
to decrease dose wherever possible, the clinical importance
of these changes in the low dose region is difficult to judge.
Considering the additional transmission and leakage dose de-
livered to the patient during more modulated and complex
deliveries, the advantages of using unconstrained intensity
limits could be diminished, or more important, outweighed,
by the increased normal tissue dose due to leakage/
FIG. 7. Head/neck case—beam intensity patterns for maximum intensity
ratios 0.85–3.71. Shown below each intensity map is the correlation coeffi-
cient with respect to the unconstrained intensity plan sMIR=3.71d, and the
monitor units per fraction required to deliver the beam via SMLC delivery.transmission. The average transmission is machine depen-
Medical Physics, Vol. 32, No. 5, May 2005dent and is approximately 2% of the total monitor units for
our linear accelerator and MLC design sVarian, 2100 EX,
Millennium MLC, Palo Alto, CAd.44 In the cases we have
shown, these transmission rates result in an average increase
in dose from the constrained to unconstrained plans of 4.0
cGy s1.7 s.d.d for the static deliveries and 3.4 cGy s2.3 s.d.d
for the dynamic deliveries. As Mohan et al. suggest, in com-
plex deliveries it is not uncommon for some points to receive
100% of their dose through indirect means.10 Thus, the extra
effort to reduce normal tissue doses by making minor inten-
sity adjustments that increase the total monitor units are
likely unproductive, and may even increase the total doses
eventually received when more accurately accounting for
transmission and leakage and geometric uncertainties. Hall
and Wu have suggested that this increased leakage radiation
may contribute to an increased risk of second malignancies,
and a joint publication by the American Society for Thera-
peutic Radiation Oncology sASTROd and the American As-
sociation of Physicists in Medicine sAAPMd has also pointed
out the compromises that must be made when considering
the increases in MU frequently seen in clinical IMRT.14,15
Table V and Figs. 2, 4, and 5 show large increases in the
number of monitor units required for the unconstrained in-
tensity plans as compared to several of the constrained inten-
sity plans. Many of these increases are due to isolated large
intensity “spikes” in the optimized beamlet distributions.
These peaks in the intensity pattern can result from artifacts
in the point-based optimization schemes used in inverse
planning and may not be necessary to produce a plan of high
quality. We can also observe in Figs. 2, 4, and 5 that most
normal tissue dose metrics reach a point where they begin to
stay fairly constant as a function of increasing maximum
intensity ratio. At this point, the correlation coefficients also
begin to converge to one. This may be due to the fact that the
optimization has reached the maximum intensity ratio at
which all important priorities are met and further increasing
the maximum intensity allows the system to produce small
fluctuations in neighboring beamlets or large changes in
single beamlets that only slightly affect the objective value.
At this point, it may no longer be necessary to allow in-
creases in the maximum beamlet intensity because the main
result is an increase in MU. However, it is important to point
out that it is not essential for the beamlet patterns to correlate
with the unconstrained beamlet patterns to a very high de-
gree. By limiting the maximum intensity, the solution space
of the problem is altered so that an equally acceptable solu-
tion could be achieved without a high degree of correlation.
Looking at all beams in the first acceptable plans for each
treatment site, we have an average correlation coefficient of
82.6% s6.9%d for brain and an average of 86.3% s6.5%d for
head/neck. The prostate correlation coefficient average is
even lower at 70.5% s10.7%d, which may be due partly to
the fact that the prostate plans had 0.5 cm by 0.5 cm beam-
lets as compared to 1 cm by 1 cm beamlets. Another factor is
that different tradeoffs were made in the cost function as can
be seen from the different shapes of the dose distributions for
prostate 1 in Fig. 3sbd.
1244 Coselmon et al.: Intensity limits for IMRT inverse planning 1244It should be noted that using an intensity limit within the
optimization search sor other constraints on beamlet intensi-
tiesd is different than applying that same kind of limit within
the leaf sequencing operation. Since the sequencer is typi-
cally independent of the optimization process, applying these
limits during sequencing ignores any clinical tradeoffs that
are made according to the cost function. Instead, the leaf
sequencer tries to achieve a sequence that matches the input
splannedd intensities, so any deviations from the planned in-
tensity are only evaluated on an intensity basis and are not
related to the actual clinical compromise that may result
from a deviation between the planned and deliverable inten-
sity map. With the delivery-related limitations sbeamlet
maximum intensity, in this cased within the plan optimization
search, the tradeoffs are made using the clinical cost function
resulting in clinically relevant compromises. The same holds
true when incorporating smoothing and hardware delivery
constraints into the optimization process.12,16–18 However, in-
corporation of delivery constraints during optimization does
not discriminate against unnecessary modulation and exces-
sive MU. Siebers et al. have shown that there is a possibility
of reducing the MU significantly by incorporating leaf se-
quencing into the optimization process, although much of the
MU reduction may have been due to intensity filtering and
smoothing in the leaf-sequencing algorithm.12
Another competing technique would be to use discrete
intensity levels for the optimization.45,46 This method would
be able to remove large intensity peaks in a similar way to
applying intensity limits if the highest intensity level was set
to a reasonable value. In addition, discretizing the intensity
levels would remove any small fluctuations between neigh-
boring beamlets that also contribute to increases in MU. One
drawback to using predefined intensities is that the degrees
of freedom are diminished for complicated cases, possibly
preventing some objectives to be met. In these cases, it may
be possible to increase the number of intensity levels through
an iterative process without significantly affecting planning
time. Gains in efficiency are also possible with more ad-
vanced leaf sequencing algorithms, leading to less discrep-
ancy between planned and delivered fields.17–21 However,
this technique is not meant to remove undesirable high-
frequency components from the planned intensity fields,
which could possibly make the plan more vulnerable to
slight geometric changes. Although a study of geometric sen-
sitivity was not performed in this work, it may follow from
the reductions seen in the plan intensity map variation values
that the intensity limited plans would be somewhat less sen-
sitive to small shifts in the patient geometry than uncon-
strained IMRT plans.
Due to the advantages in decreasing monitor units and
hence leakage dose when applying maximum intensity lim-
its, we have modified our clinical IMRT planning to incor-
porate this approach when appropriate. At this time for each
patient, an initial patient plan is optimized with uncon-
strained intensity to determine clinical compromises that are
due solely to the objective functions for the tumor and nor-
mal tissues. The resulting plan is reviewed by the physician
to determine the acceptability of the plan. Then, a dosim-
Medical Physics, Vol. 32, No. 5, May 2005etrist, based on experience and the plan information such as
the prescription dose and number of beam angles, will
choose a maximum intensity to use in reoptimizing the pa-
tient plan. If the resulting plan is acceptable to the physician
and has a significant decrease in MU after sequencing, the
constrained plan is generally accepted. While the current
process is iterative, it can typically be performed in 20 min
or less. Applying a limit to the maximum beamlet is straight-
forward in our in-house optimization system. However, lim-
iting this parameter may not be possible at this time in other
optimization systems. In that case, other approaches may be
used to obtain similar results including methods to decrease
the number of intensity levels as discussed earlier.
It is clear that the maximum intensity limits described
here or smoothing functions used on the beamlet distribution
during optimization only address a limited aspect of the gen-
eral problem, which is to decrease complexity—unless that
complexity is really needed to achieve the desired clinical
result. Other approaches, such as incorporating more ad-
vanced delivery objectives into optimization, moving away
from point-based and beamlet-based optimization, and im-
proved tradeoff evaluation tools may be necessary to make
further advances in this area.11,12
V. CONCLUSIONS
Incorporating intensity limits into the optimization pro-
cess is a simple and effective way to reduce unnecessary
beam modulation and monitor units required for delivery in
IMRT plans. In the brain, prostate, and head/neck, monitor
unit reductions up to 38%, 30%, and 29% as compared to
unconstrained intensity plans were possible while still meet-
ing planning objectives. The intensity map variation was re-
duced by up to 30% and 34% in the brain and prostate, while
the complex head/neck variation was able to be preserved
when necessary to meet the planning objectives. The dosim-
etric advantage of not constraining the maximum intensity is
an overall minimization of normal tissue dose, however this
effect may be offset by increased transmission and leakage
with greater numbers of monitor units being required for
delivery.
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